Delivery Order SPE2DB22D2211-SPE2DB24FNTP0

Award Date 6/18/24
Potential Completion Date 6/20/24
Potential Value $1.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office division is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. The contract is a Delivery Order issued by the Defense Logistics Agency (DLA), a defense agency, with a Ceiling Value of $1,971.60 and a completion date of June 6, 2024. This is a Firm Fixed Price contract. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is a delivery order valued at $5,390.80 for the HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical product. The award is under the Defense Logistics Agency (DLA) Troop Support Medical Indefinite Delivery Contract (IDC), a single-award IDC worth up to $999,999,999.00 through December 31, 2025. This IDC serves as the primary vehicle for Amerisourcebergen to provide a wide range of pharmaceutical products and...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the provision of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The award, valued at $3,154.56, is a Delivery Order under an existing Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, which is valued up to $999,999,999.00 and runs through December 31, 2025. This single-award IDC serves as the primary...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. The contract has a ceiling value of $37,158.20 and a completion date of May 29, 2024. It is a firm fixed-price delivery order issued by the Defense Logistics Agency (DLA), a defense agency. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued up to $999,999,999.00...
Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, has been awarded a $7,886.40 firm fixed price delivery order contract by the Defense Logistics Agency (DLA) to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, with a completion date of February 12, 2024. This delivery order is part of an indefinite delivery contract (IDC) valued at up to $999,999,999.00 awarded to Amerisourcebergen Drug Corp by DLA, which serves as the primary vehicle for the...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. The contract has a ceiling value of $5,914.80 and is a delivery order issued under Amerisourcebergen's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical. This single-award IDC, valued up to $999,999,999.00 through December 31, 2025, serves as the primary vehicle for...
This federal contract award to Amerisourcebergen Drug Corp is for the pharmaceutical product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The $113,657.00 firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA), a defense agency. The contract has an ultimate completion date of May 22, 2025 and is not set aside. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that serves as a critical supplier of medical and pharmaceutical products to federal agencies,...
The U.S. Department of Defense's Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical products. The delivery order, valued at $2,365.92, has a completion date of February 23, 2024. AmerisourceBergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) awarded by DLA, valued up to $999,999,999.00 with a...
This is a delivery order awarded to Amerisourcebergen Drug Corp's Corporate Office Division by the Defense Logistics Agency (DLA) Troop Support Medical. The $2,590.20 firm-fixed-price contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. The award has an ultimate completion date of July 22, 2024. Amerisourcebergen is a major pharmaceutical distributor that holds several Indefinite Delivery Contracts (IDCs) with the DLA and other federal agencies, valued up...
This federal contract award to Amerisourcebergen Drug Corp is a $5,126.16 delivery order for the product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The contract has an ultimate completion date of August 26, 2024 and was awarded on August 23, 2024. The contract is a firm fixed price arrangement with the Defense Logistics Agency (DLA), a defense agency within the Department of Defense. Amerisourcebergen is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role...
  • SPE2DB22D2211
    Indefinite Delivery Contract
  • SPE2DB22D2211-SPE2DB24FNTP0
    Delivery Order

This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The Firm Fixed Price Delivery Order, valued at $1,182.96, has a period of performance through June 20, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. This contract award does not have a set-aside designation.

Generated 9/17/24, 9:26 AM